Araris Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
28
- Latest Deal Type
-
M&A
- (Announced)
- Latest Deal Amount
-
$400M
- Investors
-
15
Araris General Information
Description
Developer of an antibody-drug conjugate (ADC) linker technology designed to deliver potent drugs specifically to the desired tissue. The company's technology is focused on creating ADCs that are powerful biopharmaceuticals, delivering highly toxic drugs, or payloads, specifically to cancer cells, molecular design enables the highly selective delivery of any payload, often a potent anti-cancer drug, to the diseased tissue, while healthy parts of the human body are spared, enabling researchers to generate efficient antibody-drug conjugates that do not need antibody engineering.
Contact Information
Website
www.ararisbiotech.comCorporate Office
- Riedhofstrasse 11
- 8804 Zurich
- Switzerland
Corporate Office
- Riedhofstrasse 11
- 8804 Zurich
- Switzerland
Araris Timeline
Araris Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 17-Mar-2025 | $400M | Announced | Generating Revenue | ||
| 8. Accelerator/Incubator | 05-May-2023 | Completed | Generating Revenue | |||
| 7. Early Stage VC | 11-Apr-2023 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 04-Oct-2022 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 22-Oct-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 27-Jun-2019 | Cancelled | Startup | |||
| 3. Accelerator/Incubator | 27-Jun-2019 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2019 | Completed | Startup |
Araris Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Araris Comparisons
Industry
Financing
Details
Araris Competitors (53)
One of Araris’s 53 competitors is Allele Biotechnology, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allele Biotechnology | Venture Capital-Backed | San Diego, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Immunophotonics | Private Equity-Backed | Saint Louis, MO |
Araris Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Araris Patents
Araris Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023223556-A1 | Peptide linkers comprising two or more payloads | Pending | 22-Feb-2022 | ||
| EP-4482529-A1 | Peptide linkers comprising two or more payloads | Pending | 22-Feb-2022 | ||
| US-20250082774-A1 | Peptide linkers comprising two or more payloads | Pending | 22-Feb-2022 | ||
| EP-4422695-A1 | Methods for producing antibody-linker conjugates | Pending | 25-Oct-2021 | ||
| US-20240398972-A1 | Methods for producing antibody-linker conjugates | Pending | 25-Oct-2021 | A61K47/65 |
Araris Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Araris Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innosuisse | Government | |||
| Kinled Holding | Family Office | |||
| Samsung Venture Investment | Corporate Venture Capital | Minority | ||
| Wille Finance | Family Office | Minority | ||
| Institute for Follicular Lymphoma Innovation | Not-For-Profit Venture Capital | Minority |
Araris Investments (2)
Araris’s most recent deal was a Corporate Asset Purchase with Innate Pharma (Portfolio of Transglutaminase Patents in Marseille, France). The deal was made on 24-Sep-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Innate Pharma (Portfolio of Transglutaminase Patents in Marseille, France) | 24-Sep-2024 | Corporate Asset Purchase | Buildings and Property | ||
| ARS Pharmaceuticals (Nectin-4 Antibody) | 17-Apr-2023 | Corporate Asset Purchase | Buildings and Property |
Araris FAQs
-
When was Araris founded?
Araris was founded in 2019.
-
Where is Araris headquartered?
Araris is headquartered in Zurich, Switzerland.
-
What is the size of Araris?
Araris has 28 total employees.
-
What industry is Araris in?
Araris’s primary industry is Biotechnology.
-
Is Araris a private or public company?
Araris is a Private company.
-
What is the current valuation of Araris?
The current valuation of Araris is .
-
What is Araris’s current revenue?
The current revenue for Araris is .
-
How much funding has Araris raised over time?
Araris has raised $43.5M.
-
Who are Araris’s investors?
Innosuisse, Kinled Holding, Samsung Venture Investment, Wille Finance, and Institute for Follicular Lymphoma Innovation are 5 of 15 investors who have invested in Araris.
-
Who are Araris’s competitors?
Allele Biotechnology, CytomX Therapeutics, Meditope Biosciences, Virometix, and Immunophotonics are some of the 53 competitors of Araris.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
